Company / SG&A Expense
Elanco SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.4B
FY2025
5-year range
$1.3B / $1.4B
FY2021-FY2025
Trend
+8.8%
vs FY2024
Sector context
#18 of 213
Health Care
What the data says
Among 213 Health Care companies, Elanco is in the bottom 8% for sg&a expense. SG&A Expense has increased for 3 consecutive years, from $1.3B in FY2022 to $1.4B in FY2025.
Based on SEC 10-K filings.
$1.4B in FY2025 with a 5-year CAGR of +7.5%. Top quartile in the Health Care sector.
Increased from $1.3B to $1.4B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +4.2%
- 5-Year CAGR
- +7.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 213This company $1.4B Sector average $722.3M
▼
+98.0% above sector average
Key checks
Key Insights
- Elanco's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +7.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 8.8% year-over-year.
- Ranks #18 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4B | +8.8% |
| FY2024 | $1.3B | +2.3% |
| FY2023 | $1.3B | +1.6% |
| FY2022 | $1.3B | -9.8% |
| FY2021 | $1.4B | +40.7% |
| FY2020 | $997.0M | +31.2% |
| FY2019 | $760.0M | +3.4% |
| FY2018 | $735.2M | -5.7% |
| FY2017 | $779.8M | -0.6% |
| FY2016 | $784.8M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026